Abstract:
Swellable particles for delivery of a drug or other working agent to the pulmonary system are provided. The swellable particles include a dehydrated (dry) aerodynamic particle diameter of 5 µm or less to enable delivery to the respiratory tract, such as for example to the tracheo-bronchial airways of the upper respiratory tract and/or to the alveolic regions of the deep lung, and a hydrated particle diameter that is greater than 6 µm volume mean diameter to retard or prevent their phagocytosis by the macrophages present in airways of the respiratory tract.
Abstract:
A semiconductor device (28) is supported by a substrate (8) with a smaller lattice constant. A metamorphic buffer (10, 12, 14, 16, 18, 20) provides a transition from the smaller lattice constant of the substrate to the larger lattice constant of the semiconductor device. In one application, the semiconductor device has a lattice constant of between approximately 6.1 and 6.35 angstroms, metamorphic buffer layers include Sb (e.g., AlInSb buffer layers), and the substrate has a smaller lattice constant (e.g., Si, InP or GaAs substrates).
Abstract:
A cap or sheath locks onto the needle or other sharp, thus permanently inactivating the needle or other sharp, preventing any further use of the device, and permanently isolating the contaminated sharp. Four components are a needle or sharp to accommodate a locking collar, a sheath with a external, internal, or horizontal track to accommodate a locking collar, a locking collar that moves inferiorly within or outside the sheath, or horizontally that binds to the sheath or needle, permanently locking the needle in the sheath and mechanically preventing the needle from moving from the sheath, and a locking mechanisms for these devices. Handles are advantageously provided for the sheath to permit safe recapping or resheathing so that the needle can be bound in the sheath and inactivated.
Abstract:
A photodetector (100) for use at wavelengths of 2 µm and longer has an intersubband absorption region (110) to provide absorption at wavelengths beyond 2 µm, integrated with an avalanche multiplier region (104) to provide low-noise gain. In one particular design, the intersubband absorption region (110) is a quantum-confined absorption region (e.g., based on quantum wells and/or quantum dots).
Abstract:
The invention provides methods for detecting the presence or absence of invasive trophoblast cells. In addition, the invention provides methods for distinguishing quiescent trophoblast diseases from invasive trophoblast diseases and methods for monitoring progression of quiescent trophoblast diseases. The invention provides methods for detecting the presence or absence of germ cell tumors.
Abstract:
The invention provides a sensing device comprising: a vessel; a plurality of sensor beads located within the vessel to form interstitial spaces there through; and a plurality of biomolecules bound to at least at portion of the plurality of beads, each of the biomolecules having a fluorescent tag. A sensing device comprised a suspension of a plurality of sensor beads. The invention also provides a method for detecting the binding of two biomolecules comprising the following steps: providing a plurality of first biomolecules, each of the first biomolecules having a first fluorescent tag; and providing a plurality of second biomolecules, each of the second biomolecules having a second fluorescent tag. The binding step have a pre-complexing total fluorescence and detecting any difference between the pre-complexing total fluorescence and the post-complexing total fluorescence.
Abstract:
In one aspect, this disclosure describes a pharmaceutical composition that generally includes frankiamicin A and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating a subject having, or at risk of having, a condition caused by a microbial infection treatable with frankiamicin A. Generally, the method includes administering to the subject an amount of frankiamicin A effective to ameliorate at least one symptom or clinical sign of the condition.
Abstract:
The present invention is a photovoltaic-thermoelectric solar cell and a method of manufacturing a photovoltaic-thermoelectric solar cell. The solar cell includes a substantially transparent electrode, an organometallic photovoltaic material disposed on the transparent electrode, and a cathode disposed on the organometallic photovoltaic material. The organometallic photovoltaic material may be a porphyrin nanomaterial.
Abstract:
In one embodiment, the invention provides a method of treating a subject who suffers from, or who is suspected of suffering from, a Mycobacterium infection, the method comprising administering to the subject a therapeutically effective amount of a urease inhibitor, optionally in combination with one or more anti-mycobacterial agents.
Abstract:
Provided is a method for determining a volume, at room temperature, of a first chamber having an unknown volume that is in fluid communication through a controllable valve with a second chamber having an unknown volume. The method can include measuring, by a pressure sensor coupled to one of the first chamber and the second chamber, a first equilibrium pressure of a gas that was introduced into the second chamber in both the first chamber and the second chamber after equilibrium is reached; measuring, by the pressure sensor, a second equilibrium pressure of the gas that was introduced into the second chamber in both the first chamber and the second chamber after equilibrium is reached, wherein the first chamber comprises an object with a known volume therein; and determining the volume of the first chamber based on the first equilibrium pressure and the second equilibrium pressure.